Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Blueprint Medicines
Biotech
Blueprint halts CDK2 inhibitor but pushes on in breast cancer
Blueprint will halt a clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer therapies.
James Waldron
Jan 13, 2025 5:43am
Blueprint drops lung cancer programs after seeing early data
Jan 9, 2024 9:22am
Blueprint's solid tumor med permitted to resume trial
Mar 29, 2023 5:00am
Blueprint's solid tumor med slapped with partial clinical hold
Feb 10, 2023 10:30am
AACR: Blueprint wants to make resistance to Tagrisso futile
Apr 8, 2022 1:00pm
A $632M protein degrader Blueprint for a nascent Vant biotech
Feb 28, 2022 8:45am
